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Abstract
Background: The biosynthesis of estrogens from androgens is catalyzed by aromatase P450 enzyme, coded by the
CYP19A1 gene on chromosome 15q21.2. Genetic variation within the CYP19A1 gene sequence has been shown to
alter the function of the enzyme. The aim of this study is to investigate whether a non-synonymous Arg264Cys
(rs700519) single nucleotide polymorphism (SNP) is associated with altered levels of circulating estradiol, areal bone
mineral density or fracture.
Methods: This population- based study of 1,022 elderly Caucasian women (mean age 74.95 ± 2.60 years) was
genotyped for the rs700519 SNP were analyzed to detect any association with endocrine and bone phenotypes.
Results: The genotype frequencies were 997 wildtype (97.6%), 24 heterozygous (2.3%) and 1 homozygous (0.1%).
When individuals were grouped by genotype, there was no association between the polymorphism and serum
estradiol (wildtype 27.5 ± 16.0; variants 31.2 ± 18.4, P = 0.27). There was also no association seen on hip bone
mineral density (wildtype 0.81 ± 0.12; 0.84 ± 0.14 for variants, P = 0.48) or femoral neck bone mineral density (0.69
± 0.10 for wildtype; 0.70 ± 0.12 for variants, P = 0.54) before or after correction of the data with age, height,
weight and calcium therapy. There were also no associations with quantitative ultrasound measures of bone
structure (broadband ultrasound attenuation, speed of sound and average stiffness).
Conclusions: In a cohort of 1,022 elderly Western Australian women, the presence of Arg264Cys (rs700519)
polymorphism was not found to be associated with serum estradiol, bone structure or phenotypes.
Background
Aromatase P450 enzyme (CYP19A1) is located in the
endoplasmic reticulum of cells that synthesize estrogen,
it catalyses the conversion of C19 steroidal androgens,
testosterone, androstenedione and hydroxyl androstene-
dione into C18 steroidal estrogens estradiol, estrone and
estriol, respectively. Bone structure, as measured by dual
energy-x-ray absorptiometry (DXA) areal bone mineral
density (aBMD) is a phenotype dependent on circulating
estradiol in postmenopausal women [1]. Another non-
invasive modality of bone structural assessment, heel
quantitative ultrasound and its modalities (including
broadband ultrasound attenuation (BUA) speed of
sound (SOS) and average stiffness) are also related to
estradiol production [2].
The aromatase enzyme is encoded for by the
CYP19A1 gene which is localized on 15q21.2 and spans
approximately 131 Kb. Individual genetic variations in
the aromatase sequence have previously been described
that have substantial phenotypic effects. For example a
homozygous single base change at bp 1123 (C®T) can
lead to severe generalized aromatase deficiency [3] while
a TTTA repeat polymorphism has also been shown to
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any medium, provided the original work is properly cited.be associated with circulating estrogen, bone structure,
and biochemistry in older women [4].
Four non-synonymous coding SNPs, Trp39Arg,
Met364Thr, Thr201Met and Arg264Cys, have been stu-
died to date [5]. Trp39Arg is a rare polymorphism asso-
ciated with breast cancer [6]. Met364Thr, observed only
in the Han Chinese-American samples, is related to a
significant decrease in affinities for the androgen sub-
s t r a t e[ 7 ]w h i l s tt h eT h r 2 0 1 M e tv a r i a n ti sr e l a t e dt oa n
increase in the aromatase enzyme activity [8]. In this
study, associations between the sequence variant
rs700519 (Arg264Cys) in exon 7 of the CYP19A1 gene,
estradiol and bone phenotypes were examined.
Methods
Subjects
The rs700519 SNP was genotyped in 1,022 individuals
who participated in the Calcium Intake Fracture Out-
come Study (CAIFOS), a 5-year randomised controlled
trial looking into the effects of calcium supplementation
in prevention of osteoporotic fractures [9]. The subjects
were all Caucasian women, aged 70 to 85 years and
represented a random population sample of this age
group. No participant was retained in the study if they
were taking any medication that would have a known
effect on bone metabolism or were suffering from a dis-
ease that suggested the subject would be unlikely to sur-
vive for 5 years. Subjects received either 1.2 g of
elemental calcium in the form of calcium carbonate or
placebo daily. At baseline all participants completed a
lifestyle questionnaire and had their height and weight
measured. The study was approved by Human Research
Ethics Committee office of Sir Charles Gairdner Hospi-
tal, Western Australia. All participants gave informed
consent for the study.
Areal bone mineral density and quantitative ultrasound
measurements
At baseline, quantitative ultrasound (QUS) of the left
calcaneus was measured twice in all subjects. Measure-
ments were taken using Lunar Achilles ultrasound
machine (Lunar Corp, USA) employing the manufac-
turer’s quality assurance methods. The average of the
two measurements of speed-of-sound (SOS), broadband
ultrasound attenuation (BUA) and stiffness were
recorded and used in the analyses. Using the manufac-
turer’s standards, the coefficients of variation (CV) for
SOS and BUA were 0.43% and 1.59% respectively [1].
Areal bone mineral density (aBMD) was measured
using dual-energy X-ray absorptiometry (DXA) on a
Hologic 4500A machine (Hologic, Boston, MA, USA) at
the total hip and femoral neck regions at year 1 of the
study. The CV at the total hip and femoral neck were
1.0% and 1.4% respectively [1].
Fracture status
Clinical incident fracture due to a minimal trauma, as
defined by falling from a height of less than 1 metre,
was assessed during the 84 month follow-up using
radiographic reports. Fractures of the face, skull, fingers
and toes were not included.
Biochemistry
At baseline a blood sample from each subject was col-
lected following an overnight fast. Serum estradiol was
measured using a radioimmunoassay (Orion Diagnos-
tica, Finland) inter-assay CV 5.0% at 18 pmol/L and
6.6% at 100 pmol/L, intra-assay CV 5.0% at 100 pmol/
L). Sex hormone-binding globulin (SHBG) was mea-
sured using an immunochemiluminometric assay (Imu-
lite Co., LA, USA) the inter- and intra-assay CVs were
6.8% and 7.1%, respectively at 24 nmol/L. The free
estradiol index (FEI) was calculated as the molar ratio of
estradiol to SHBG. Genomic DNA was extracted and
purified from ethylenediamine tetra-acetic acid (EDTA)-
prepared peripheral blood for genotyping analyses [1].
rs700519 SNP genotyping
rs700519 SNP in the CYP19A1 gene was analysed using
a Restriction Fragment Length Polymorphism (RFLP)
method. In brief, the PCR reaction consisted of: 1x PCR
buffer, 0.2 mM dNTP mix (Promega, USA), 0.5 mM
MgCl2 solution, 1.5 uM of each of each sequence speci-
fic forward (5’ GGCAAATAAATCTGTTTCGCTAGA
3’) and reverse (5’ CAACTCAGTGGCAAAGTCCA 3’)
primer (Sigma Aldrich, Australia), 0.5 U of HotStarTaq
Plus DNA polymerase and 20 ng of DNA made up to a
final reaction volume of 20 μlu s i n gP C Rg r a d eH 2O.
The PCR cycling conditions were 95°C for 5 min, 35
cycles of 94°C for 1 min, 68°C for 1 min and 72°C for 1
min followed by a final extension at 72°C for 10 min.
The PCR product was digested with 1 U of the restric-
tion enzyme HpyCH4V at 37°C for 2 hours and the pro-
duct analysed by electrophoresis on an agarose gel (2%).
A positive control was included in each reaction.
In these analyses, individuals who had the rs700519
wildtype genotype displayed a 173 bp amplicon, while
those heterozygous had bands at 173 bp, 118 bp and 55
bp and individuals who were homozygous for the rare
variant, revealed bands at 118 bp and 55 bp.
Data and statistical analysis
Statistical analysis was performed using SPSS (SPSS Inc.,
Chicago, IL, USA, version 16). For association testing a
dominant model was used. The differences in phenoty-
pic means for each genotype group were examined
using analysis of covariance (ANCOVA), with the cov-
ariates age, height, weight and calcium therapy incorpo-
rated in the analysis of BMD and QUS; while age and
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n o t y p e s .T h ef r a c t u r ep h e n o t y p e sw e r ec o m p a r e db y
Cox regression adjusted for age, weight, height and cal-
cium therapy. A post hoc power calculation was under-
taken to estimate the probability of a Type 2 error
occurring in the study [10].
Results
Characteristics of study population
The demographics, bone density, QUS and biochemistry
data for the CAIFOS population are presented in Table
1.
Association between SNP rs700519, estradiol and bone
phenotypes
The genotype frequencies were 997 wildtype (97.6%), 24
heterozygous (2.3%) and 1 homozygous (0.1%) for the
variant. Age, height, weight and BMI were not signifi-
cantly different between the groups. There were no
associations between genotype and circulating estradiol,
SHBG and FEI. For bone phenotypes there were no
associations between aBMD before and after adjusted
for age, height, weight and calcium therapy both for
total hip and femoral neck sites or ultrasound bone phe-
notypes including BUA, SOS and average stiffness. No
association was evident between genotypes and total,
hip or vertebral fracture incidence over 84 months
(Table 2).
Assuming a QTL variance of 1% with a marker fre-
quency of 0.013, where this marker is hypothesized to
be the disease variant, at an alpha of 0.05 the sample
size of 1,022 had statistical power of 0.83.
Discussion
The Arg264Cys polymorphism causes a non-synon-
ymous amino acid substitution which was not associated
with bone or estradiol phenotypes in this cohort of
elderly Caucasian women. Our study had sufficient sta-
tistical power to detect even relatively small effects and
so the lack of association is unlikely to be due to a type
II error.
This lack of effect on endocrine and bone metabolism
phenotypes is generally supported by several previous
studies of the Arg264Cys polymorphism in relation to
breast cancer. Watanabe et al. reported that in Japanese
women, the polymorphism had no relationship to the
risk of breast cancer and did not affect an in vitro assay
of aromatase activity using test using the tritiated water
release assay in transfected COS-7 cells [11]. A case-
control study in Austria repo r t e dt h a tt h i sp o l y m o r p h -
ism did not affect breast cancer or fibroadenoma risk
[12] while in an in vitro study focusing on aromatase
activity in breast cancer tissue, an Arg264Cys heterozy-
gote was found but showed no alteration of aromatase
activity [13].
In contrast, Ma et al. undertook studies using tritiated
water release assays in, COS-1, cells transfected with
cDNA containing the wild type and variant sequence of
rs700519 [5]. The Km value of wide-type was reported
to be 6.7 ± 2.0 nmol/L as compared to Arg264Cys 5.9 ±
2.6 nmol/L (mean ± SE, P=0.0001). However this
Table 1 Demographics, bone density, quantitative
ultrasound, and bone biochemistry of the CAIFOS
population (n = 1022)
Variable Mean ± SD
Age (years) 74.9 ± 2.6
Weight (Kg) 68.4 ± 11.9
Height (cm) 159.0 ± 5.8
BMI (kg/m
2) 27.1 ± 4.5
Total hip BMD (mg/cm
2) 0.8 ± 0.1
Femoral neck BMD (mg/cm
2) 0.7 ± 0.1
Total fracture in 84 months (yes/no) 205 (20.1%)
Hip fracture in 84 months (yes/no) 29 (2.8%)
Vertebral fracture in 84 months (yes/no) 71 (6.9%)
Estradiol (pmol/L) 27.6 ± 16.1
SHBG (nmol/L) 54.9 ± 23.7
Free estradiol index (units) 2.9 ± 3.0
Average BUA (dB/MHz) 100.4 ± 7.6
Average SOS (m/s) 1512.6 ± 24.9
Average stiffness (%) 70. 5 ± 11.0
Results in mean ± SD or number (percentage).
Table 2 BMS, QUS and sex hormone biochemistry
parameters in relation to the distribution of the
rs700519 genotype in CAIFOS study (n = 1022)
Variable Wild type Variants P
value
Number 997 25
Age (years) 74.95 ± 2.60 74.91 ± 2.76 0.83
Weight (Kg) 68.32 ± 11.79 72.19 ± 15.85 0.11
Height (cm) 158.96 ± 5.86 159.35 ± 4.67 0.74
BMI (kg/m
2) 27.03 ± 4.39 28.53 ± 6.81 0.10
Total fractures (yes/no) 198 (19.9%) 7 (28.0%) 0.27
Hip fractures (yes/no) 28 (2.8%) 1 (4.0%) 0.76
Vertebral fractures n (yes/
no)
69 (6.9%) 2 (8.0%) 0.83
Total hip BMD (mg/cm
2) 0.81 ± 0.12 0.84 ± 0.14 0.48
Femoral neck BMD (mg/
cm
2)
0.69 ± 0.10 0.70 ± 0.12 0.54
Average BUA (dB/MHz) 100.45 ± 7.61 99.46 ± 8.90 0.21
Average SOS (m/s) 1512.62 ±
24.66
1512.83 ±
33.87
0.90
Average stiffness (%) 70.52 ± 10.89 69.83 ± 14.90 0.50
Estradiol (pmol/L) 27.51 ± 16.00 31.16 ± 18.36 0.27
SHBG (nmol/L) 55.03 ± 23.81 50.52 ± 19.73 0.33
Free estradiol index (units) 2.95 ± 3.01 2.50 ± 2.10 0.43
Results in mean ± SD or number (percentage). P value generated using
ANCOVA test or COX regression.
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with both Arg39 and Arg264Cys which may have
affected the interpretation of their results. Thus it
r e m a i n sp o s s i b l et h a tt h ea s s a yu s e db yM ae ta ld o e s
not reflect estradiol production in the adipocytes of
postmenopausal women, the major source of circulating
estradiol in the women studied in this paper. Another
study, in a group of 1,136 Chinese breast cancer patients
[14], reported that rs700519 was associated with breast
cancer disease-free survival with an age-adjusted hazards
ratio for the homozygote (Cys/Cys) of 2.2 (95%, CI 1.2-
4.1), but did not report serum estradiol levels.
Ethnic groups show substantial differences in the allele
frequency of Arg264Cys, estimates suggest that the Japa-
nese population has a minor allele frequency (MAF) of
27.3%, in Chinese the MAF is 11.6%, for sub Saharan
Africans 21.4% and European populations, 3.1% [15].
Our study shows a MAF of 1.3%, which was similar to
the study in UK showing low frequency of Arg264Cys in
British people [16].
Conclusions
In conclusion this CYP19A1 gene Arg264Cys (rs700519)
polymorphism has no effect on circulating estradiol or
bone phenotypes in elderly Caucasian women. Whether
i ti sp o s s i b l et h a tt h i sS N Ph a sa ne f f e c to nb r e a s tc a n -
cer epidemiology or hormone metabolism in premeno-
pausal women remains uncertain and will need to be
determined from further study.
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